← Leaderboards
Sara J. Ward
University Of North Carolina Chapel Hill
$5,152,771
Attributed
$7,664,951
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,664,951 · 9
By mechanism
R42$2,970,772 · 1
R01$2,377,500 · 1
R21$1,753,673 · 4
R41$299,916 · 1
F32$146,402 · 1
R03$116,688 · 1
Top collaborators
- Douglas Eric Brenneman4 shared
- Eugen Brailoiu2 shared
- Erica A Golemis2 shared
- Scott M Rawls1 shared
- Namrata Vijayvergia1 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseCannabinoidsCannabidiolInvestigationCannabisPreventPaclitaxelPharmacologyPainful NeuropathyInterestPainCannabis Sativa PlantChemotherapyResponseAcuteRattusAnti-Inflammatory AgentsMouse ModelReportingAttenuatedAgonistPropertyExperimental StudyLaboratories
Grant awards (21)
Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study$429,162
R21 · FY2025 · CA
Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways$199,821
R21 · FY2024 · CA
Deciphering the complex pharmacology of CB1: towards the understanding of a third signaling pathway$198,125
R21 · FY2024 · DA
Development of KLS-13019 for Neuropathic Pain$1,001,774
R42 · FY2023 · NS
Kratom and Cannabinoid Constituents: Mechanisms and Interactive Effects in Neuropathic Pain$433,710
R21 · FY2023 · AT · contact PI
Analgesic efficacy of single and combined minor cannabinoids and terpenes$396,250
R01 · FY2023 · AT · contact PI
Interaction of cannabidiol (CBD) with targeted inhibitors of essential cancer signaling pathways$255,105
R21 · FY2023 · CA
Deciphering the complex pharmacology of CB1: towards the understanding of a third signaling pathway$237,750
R21 · FY2023 · DA
Development of KLS-13019 for Neuropathic Pain$991,944
R42 · FY2022 · NS
Analgesic efficacy of single and combined minor cannabinoids and terpenes$396,250
R01 · FY2022 · AT · contact PI
Development of KLS-13019 for Neuropathic Pain$977,054
R42 · FY2021 · NS
Analgesic efficacy of single and combined minor cannabinoids and terpenes$396,250
R01 · FY2021 · AT · contact PI
Analgesic efficacy of single and combined minor cannabinoids and terpenes$396,250
R01 · FY2020 · AT · contact PI
Analgesic efficacy of single and combined minor cannabinoids and terpenes$396,250
R01 · FY2020 · AT · contact PI
Analgesic efficacy of single and combined minor cannabinoids and terpenes$396,250
R01 · FY2019 · AT · contact PI
Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence$299,916
R41 · FY2018 · DA · contact PI
Improved analgesia and safety of CBD over THC or THC+CBD: dose-addition analysis$116,688
R03 · FY2014 · DA · contact PI
CB1 Receptors: Cocaine Reinforcement and Relapse$52,182
F32 · FY2007 · DA · contact PI
CB1 Receptors: Cocaine Reinforcement and Relapse$50,499
F32 · FY2006 · DA · contact PI
CB1 Receptors: Cocaine Reinforcement and Relapse$23,178
F32 · FY2005 · DA
CB1 Receptors: Cocaine Reinforcement and Relapse$20,543
F32 · FY2005 · DA